Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098526 | 0.86 | GRN (0.38) | GAAALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL17483039 | 0.84 | ALDH1A1 (0.43) | HPGDGAAALDH1A1KDM4EMAPT | |
| SCHEMBL27373206 | 0.80 | GAA (0.39) | HPGDGAAALDH1A1KDM4EMAPT | |
| SCHEMBL30852390 | 0.80 | GAA (0.39) | HPGDGAAALDH1A1KDM4EMAPT | |
| SCHEMBL18613612 | 0.72 | ABL1 (0.43) | HPGDGAAALDH1A1KDM4EMAPT | |
| SCHEMBL30852383 | 0.72 | P2RX7 (0.44) | ALDH1A1KDM4EALOX12KMT2ALMNA | |
| SCHEMBL27373031 | 0.72 | P2RX7 (0.44) | ALDH1A1KDM4EALOX12KMT2ALMNA | |
| SCHEMBL23486513 | 0.71 | KDM4E (0.43) | GAAALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL30852354 | 0.71 | KDM4E (0.40) | HPGDALDH1A1KDM4EKMT2AOR51E2 | |
| SCHEMBL30852329 | 0.70 | MAPT (0.47) | HPGDALDH1A1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2014152835-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | KYNU, KMO, AADAT | HPGD 216/4885GAA 3038/4885ALDH1A1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.